Page 3 - Program Milestones News Today : Breaking News, Live Updates & Top Stories | Vimarsana

I would like to welcome you to the university of minnesota. We have a terrific program here today talking about the significance of the budget deal reached in washington in terms implicationscal for both the democratic and republican parties as well as the origins of some of what we have been seeing in washington. We have a terrific panel. I would like to introduce the panel. , he served gutknecht in 12 for 12 years in the minnesota house and 12 years in the United States house of representatives. , who servedin sabo for a long time in the minnesota house of representatives, including a speake...

LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat

Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of...

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF